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Abstract
Introduction: Refractory pleural effusion in systemic immunoglobulin light chain amyloidosis without cardiac
decompensation is rarely reported and has a poor prognosis in general (a median survival of 1.6 months).
Moreover, the optimum treatment for this condition is still undecided. This is the first report on the successful use
of vincristine, adriamycin and dexamethasone chemotherapy for refractory pleural effusion due to systemic
immunoglobulin light chain amyloidosis without cardiac decompensation.
Case presentation: We report the case of a 68-year old Japanese male with systemic immunoglobulin light chain
amyloidosis presenting with bilateral pleural effusion (more severe on the right side) in the absence of cardiac
decompensation that was refractory to diuretic therapy. The patient was admitted for fatigue, exertional dyspnea,
and bilateral lower extremity edema. He had been receiving intermittent melphalan and prednisone chemotherapy
for seven years. One month before admission, his dyspnea had got worse, and his chest radiograph showed
bilateral pleural effusion; the pleural effusion was ascertained to be a transudate. The conventionally used
therapeutic measures, including diuretics and thoracocentesis, failed to control pleural effusion. Administration of
vincristine, adriamycin, and dexamethasone chemotherapy led to successful resolution of the effusion.
Conclusion: Treatment with vincristine, adriamycin, and dexamethasone chemotherapy was effective for the
refractory pleural effusion in systemic immunoglobulin light chain amyloidosis without cardiac decompensation
and appears to be associated with improvement in our patient’s prognosis.
Introduction
Systemic immunoglobulin light chain (AL) amyloidosis
is a rare disorder characterized by the extracellular
deposition of amyloid fibrils resulting from the forma-
tion of insoluble aggregates of b-pleated sheets, which
are derived from monoclonal light chains. It may lead to
progressive multiple-organ failure and death.
Recent studies have suggested that the prognosis of
systemic AL amyloidosis without pleural effusion is
improved by novel approaches, including vincristine,
adriamycin, and dexamethasone (VAD) chemotherapy
and high-dose myeloablative chemotherapy with autolo-
gous stem cell transplantation support. In particular, the
median duration of patient survival with VAD che-
motherapy (64 to 65 months) is higher than that with
intermittent melphalan and prednisone (MP) che-
motherapy [1].
However, little is known concerning whether the
refractory pleural effusion in systemic AL amyloidosis
without cardiac decompensation is associated with a
poor prognosis in general (a median survival of 1.6
months) because this complication is rarely reported
(6%) [2]. Hence, new therapies and the mechanisms of
systemic AL amyloidosis with refractory pleural effusion
needs to be discussed further.
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therapies for pleural effusion in systemic AL amyloidosis
has been evaluated by some previous studies [2-6], the
most effective therapy remains unidentified. Pleurodesis
is often required because pleural effusion is refractory to
most therapies. Although pleurodesis temporarily allevi-
ates the symptoms, its effectiveness for improving the
prognosis of systemic AL amyloidosis remains to be
clarified.
We used chemotherapy for the first time to success-
fully manage refractory pleural effusion due to systemic
AL amyloidosis without cardiac decompensation. VAD
chemotherapy may improve the prognosis of this
complication.
Case presentation
A 68-year-old Japanese male with systemic AL amyloi-
dosis was admitted with fatigue, exertional dyspnea, and
bilateral lower-extremity edema. He had been diagnosed
with systemic AL amyloidosis in 1999, on the basis of
the results of histopathological examination of the biop-
sied tissues of his kidney and bone marrow. After diag-
nosis, he was successfully managed with 21 courses of
intermittent MP chemotherapy for seven years. Two
months before admission, he developed exertional dys-
pnea. One month before admission, his dyspnea had
become worse, and his chest radiograph showed bilat-
eral pleural effusion, with the effusion on the right side
being more severe. Thoracocentesis was performed with
removal of one litre of yellow serous fluid from the
right hemithorax. Pleural fluid analysis revealed that his
nucleated cell count was 2600/mm
3 (24% neutrophils,
71% lymphocytes); total protein concentration, 0.4 g/dl
(a pleural fluid to serum ratio, 0:11); lactate dehydrogen-
ase level, 26 IU/l (two-thirds normal upper limit for
serum, 154 IU/l and a pleural fluid to serum ratio, 0:12);
total cholesterol content, 11 mg/dl; and glucose level,
118 mg/dl. These findings were consistent with transu-
dative pleural effusion. The pleural fluid cytology was
negative for malignancy. The pleural fluid was cultured
for bacteria (aerobic and anaerobic), fungi, and myco-
bacteria, and the results were negative.
Since the pleural effusion was refractory to aggressive
administration of diuretics, thoracentesis with removal
of one litre of serous fluid was repeated once every
week. Although his symptoms were alleviated, the
patient’s pleural effusion gradually increased and the
pleural fluid returned to the pre-drainage level after one
week. The composition of the pleural fluid remained the
same at all instances of drainage.
He was admitted to our hospital for treatment of
refractory pleural effusion. On admission, he appeared
to be comfortable while resting. He was 158.7 cm tall
and weighed 65.2 kg. His body temperature was 36.5°C;
blood pressure was 124 over 69 mm Hg; and his pulse
rate, regular at 84 beats per minute. Diminished breath
sounds in the right lower lung, slight inspiratory coarse
crackles in the left basal lung, and lower extremity
edema were observed. The results of the other clinical
examinations were normal. Laboratory tests revea-
led that his blood urea nitrogen (31 mg/dl) and serum-
creatinine (1.3 mg/dl) levels were elevated; creatinine
clearance rate was low (39 ml/min/1.73 m
2); 24-hour
urine protein was 3.5 g per day; and total protein con-
tent (4.6 g/dl) and serum-albumin levels (1.6 g/dl) were
low. These findings were indicative of renal insufficiency
and nephritic syndrome. However, his renal function
and his serum-albumin levels remained the same as
those observed one year before. The serum protein elec-
trophoresis was negative for a monoclonal spike. Bence-
Jones proteins were not detected in the urine. All his
immunoglobulin levels were normal. His hemoglobin
level was 12.4 g/dl, platelet count 12 × 10
4/mm
3,
and white blood cell count, 5900/mm
3,w i t han o r m a l
differential count. His levels of troponin T (below
0.01 mg/dl) and the C-reactive protein (0.2 mg/dl) were
a l s on o r m a l .N oo t h e ra b n o rmalities were detected in
any other laboratory tests. Our patient’s echocardiogram
showed symmetrical thickening of the left ventricular
(LV) wall with slightly high echoic lesions (interventri-
cular septum wall thickness, 14 mm; posterior LV wall
thickness, 15 mm at systolic phase) and almost normal
cardiac function (fractional shortening, 40%; LV ejection
fraction, 0.71). These results were suggestive of infiltra-
tive cardiomyopathy, and not acute heart failure caused
by cardiac compensation.
At admission, his chest radiograph image showed a
moderate effusion on the right side and slight effusion in
the left. The computed tomography imaging of his chest
revealed moderate pleural effusion in the right lung and
atelectasis of the right lower robe (Figure 1A, B).
Thoracentesis was performed with removal of one litre
of serous fluid from the right hemithorax on the second
hospital day. The level and composition of the effusion
were the same as those seen before. VAD chemotherapy
was administered on the third day. He did not develop
serious bone marrow suppression or complications. A
week after the administration of VAD chemotherapy, his
chest radiograph revealed significant improvement.
Moreover, he did not have dyspnea or general fatigue.
However, the edema in his lower extremities showed no
improvement, and no obvious change was seen in car-
diac indices; pleural effusion did not recur until he was
discharged from the hospital (Figure 1C, D). The results
of the clinical test did not change (creatinine clearance
rate, 35 ml/minute/1.73 m
2; daily proteinuria, 3.4 g;
serum-albumin, 1.6 g/dl). He was discharged from our
hospital on his 31
st hospital day.
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MP chemotherapy. Pleural effusion did not recur for six
months after he became ambulatory. However, he had a
recurrence of right pleural effusion and was managed
with VAD chemotherapy. Although his right pleural
effusion did not increase while treating with VAD che-
motherapy, the recurrence occurred immediately after
VAD chemotherapy had finished. Hence, in 2006, he
underwent chemical pleurodesis for recurrent right
pleural effusion. After pleurodesis, his pleural effusion
has not increased after he received intermittent MP che-
motherapy in 2010.
Discussion
Pleural effusion in systemic AL amyloidosis is generally
considered to be caused by heart failure, nephritic syn-
drome, and renal insufficiency. The poor prognosis of
pleural effusion is attributed to cardiac amyloidosis.
However, earlier studies have reported that in the
absence of cardiac decompensation due to cardiac amy-
loidosis, the prognosis for untreated patients with
pleural effusion is shorter than that for patients without
pleural effusion (1.6 months vs. 6 months: a median sur-
vival) [2]. Moreover, pleural effusion in the patient in
our report was completely cured by one cycle of VAD
chemotherapy with no change in serum-albumin levels
and cardiac and renal function. These findings imply
that refractory pleural effusion associated with systemic
AL amyloidosis should be considered a manifestation of
the disease just like cardiac and renal amyloidosis and
not as one of the symptoms of cardiac decompensation
and renal disorder.
Earlier reports stated that refractory pleural effusion in
systemic AL amyloidosis tended to be treated by pleur-
odesis. Although pleurodesis represents the gold stan-
dard for the treatment of massive recurrent pleural
AC
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Figure 1 Pleural effusion was significantly alleviated by vincristine, adriamycin and dexamethasone chemotherapy. Chest radiograph
(A) and computed tomography imaging (B) showing pleural effusion at admission. Chest radiograph (C) and computed tomography imaging
(D) showing significant improvement 30 days after VAD.
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ciated with risks of infection and pneumothorax [2].
Hence, to manage the refractory pleural effusion, we
administered VAD chemotherapy as an initiation ther-
apy before pleurodesis.
This is the first report on the successful use of VAD
chemotherapy for refractory pleural effusion in systemic
AL amyloidosis without cardiac decompensation. This
therapy was not invasive and reduced pleural effusion
within a short time. Hence, VAD chemotherapy may
become an effective treatment for refractory pleural
effusion resulting from systemic AL amyloidosis. How-
ever, whether VAD chemotherapy can be used as the
initial therapy before pleurodesis remains to be clarified.
Doxorubicin, vincristine, and dexamethasone, which are
included in the VAD regimen, can cause cardiac toxi-
city, neuropathy, and infection, respectively. Therefore,
VAD chemotherapy should be administered after careful
consideration.
Infiltrative cardiomyopathy revealed in an echocar-
diogram may be caused by the amyloid deposition,
which has the potential to alter regional cardiac
mechanics, resulting in LV dyssynchrony and cardiac
decompensation [7]. Although the mechanisms by
which VAD ameliorate the infiltrative cardiomyopathy
are still unclear, a recent report suggests that the
reduction of amyloid depositions resulting from
decreased precursor protein may be the mechanism by
which VAD exert their therapeutic effects [8]. The car-
diac function of this patient remained unchanged after
administration of VAD chemotherapy; however, a simi-
lar pathogenic mechanism may be involved in the
development of refractory pleural effusion without car-
diac decompensation. Previous reports on pathological
findings of tissue samples obtained by needle biopsies
have indicated that amyloid depositions in the parietal
pleura play an important role in the pathogenesis of
pleural effusion by inhibiting the absorption of pleural
fluid by interfering with the lymphatic drainage
[2,3,6,9]. Hence, amyloid depositions in the parietal
pleura may be directly reduced by VAD chemotherapy.
However, we thought that pleural effusion was not a
direct effect of amyloid protein accumulation in the
lymph duct because one cycle of VAD chemotherapy
alleviated the pleural effusion in our patient within a
week. We hypothesized that the indirect effect of amy-
loid deposition was more important than its direct
effect on the pathogenesis of pleural effusion.
Several reports have suggested that pleural effusion
may be caused by increased permeability of the pleural
capillaries [9]. Moreover, it has been reported that vas-
cular endothelial growth factor (VEGF) expression
increased in systemic AL amyloidosis [10] and that bev-
acizumab (a monoclonal antibody against VEGF) was
effective in the management of refractory pleural effu-
sion [4,5]. Therefore, we thought that VAD chemother-
apy may be as effective as bevacizumab in alleviating
pleural effusion by inhibiting VEGF expression. The
mechanisms of their action need to be elucidated
further.
We report that thalidomide [11], lenalidomide (an
analog of thalidomide) [12] and bortezomib (a proteo-
some inhibitor) [13] may have potentially important
roles for treating refractory pleural effusion accompa-
nying systemic AL amyloidosis because these drugs
have been reported to inhibit the expression of VEGF
[14-16]. It has been observed that these drugs pose a
lower risk of infection than conventional chemother-
apy. Hence, these drugs may represent important alter-
native therapeutic agents for alleviating refractory
pleural effusion due to systemic AL amyloidosis. In
addition, a combination of these drugs and conven-
tional chemotherapy may improve the prognosis of
this disease.
However, further investigations are needed to eluci-
date the relationship between VEGF and refractory
pleural effusion associated with systemic AL amyloidosis
because the complete reduction of pleural effusion was
observed in only two of the five patients reported to be
treated with bevacizumab [4,5].
Conclusion
Management of patients with systemic AL amyloidosis
who present with refractory pleural effusion is extremely
difficult and is associated with a poor prognosis. To the
best of our knowledge, this is the first report on the
administration of VAD chemotherapy for refractory
pleural effusion in systemic AL amyloidosis without car-
diac decompensation. This treatment may be effective
and afford a high quality of life for the patient.
In general, VAD chemotherapy is known to improve
the prognosis of systemic AL amyloidosis, and the Guide-
line Working Group of United Kingdom, Myeloma
Forum, recommends VAD chemotherapy as the first-line
therapy for patients aged under 70 years [17]. Therefore,
we suggest that VAD chemotherapy is clinically useful
for regulating systemic AL amyloidosis-associated refr-
actory pleural effusion.
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